Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway

Stem Cell Research and Therapy

Volumn 4, Issue 5, 2013, Pages

  Atsuta, Ikiru ^a,b   Liu, Shiyu ^a,c   Miura, Yasuo ^d   Akiyama, Kentaro ^a,e   Chen, Chider ^a   An, Ying ^c   Shi, Songtao ^a,c   Chen, Fa Ming ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d OSAKA RED CROSS HOSPITAL   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FAS PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DENSITY; CANCER INHIBITION; COCULTURE; CONTROLLED STUDY; FEMUR NECK; IN VITRO STUDY; KIDNEY METASTASIS; LUMBAR SPINE; LUNG METASTASIS; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS INHIBITION; MOUSE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; BONE; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; FEMALE; KIDNEY TUMOR; LUNG TUMOR; MESENCHYMAL STROMA CELL; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BONE AND BONES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICE, NUDE; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84883623682     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt322     Document Type: Article

References (62)

1. Molecular pathogenesis and a consequent classification of multiple myeloma. Bergsagel PL, Kuehl WM, J Clin Oncol 2005 23 6333 6338 10.1200/JCO.2005.05.021 16155016 (Pubitemid 46218843)
2. Advances in the understanding of myeloma bone disease and tumour growth. Yaccoby S, Br J Haematol 2010 149 311 321 10.1111/j.1365-2141.2010.08141.x 20230410
3. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Giuliani N, Rizzoli V, Roodman GD, Blood 2006 108 3992 3996 10.1182/blood-2006- 05-026112 16917004 (Pubitemid 44913267)
4. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ, J Clin Oncol 2007 25 1121 1128 10.1200/JCO.2006.08. 5803 17296972 (Pubitemid 46596765)
5. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. Li X, Ling W, Khan S, Yaccoby S, J Bone Miner Res 2012 27 1635 1648 10.1002/jbmr.1620 22460389
6. The association of blood lead level and cancer mortality among whites in the United States. Jemal A, Graubard BI, Devesa SS, Flegal KM, Environ Health Perspect 2002 110 325 329 10.1289/ehp.02110325 11940448 (Pubitemid 34308594)
7. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V, Blood 2005 106 2472 2483 10.1182/blood-2004-12-4986 15933061 (Pubitemid 41510822)
8. Role of decorin in the antimyeloma effects of osteoblasts. Li X, Pennisi A, Yaccoby S, Blood 2008 112 159 168 10.1182/blood-2007-11-124164 18436739
9. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Giuliani N, Mangoni M, Rizzoli V, Exp Hematol 2009 37 879 886 10.1016/j.exphem.2009.04.004 19446662
10. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr, Blood 2007 109 2106 2111 10.1182/blood-2006-09-047712 17068150 (Pubitemid 46348212)
11. A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P, Hideshima T, Santo L, Cirstea D, Scadden DT, Anderson KC, Raje N, Leukemia 2011 25 1174 1181 10.1038/leu.2011.43 21403648
12. Stem cell transplantation for multiple myeloma. Gasparetto C, Cancer Control 2004 11 119 129 15024348 (Pubitemid 38596196)
13. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, Umezawa A, Kijima H, Fukuda S, Saijo Y, Mol Med 2011 17 579 587 21424106
14. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd, Stem Cells 2011 29 11 19 10.1002/stem.559 21280155
15. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy JD Jr, van Rhee F, Nair B, Barlogie B, Epstein J, Yaccoby S, Stem Cells 2011 29 263 273 10.1002/stem.572 21732484
16. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD Jr, Zhan F, Blood 2010 115 61 70 10.1182/blood-2009-03-210526 19837979
17. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. Waterman RS, Henkle SL, Betancourt AM, PLoS One 2012 7 45590 10.1371/journal.pone.0045590 23029122
18. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA, Stem Cells 2006 24 986 991 10.1634/stemcells.2005-0220 16293576 (Pubitemid 44464731)
19. The CD95 receptor: apoptosis revisited. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zörnig M, Lynch DH, Cell 2007 129 447 450 10.1016/j.cell.2007.04.031 17482535 (Pubitemid 46660984)
20. The many roles of Fas receptor signalling in the immune system. Strasser A, Jost PJ, Nagata S, Immunity 2009 30 180 192 10.1016/j.immuni.2009.01.001 19239902
21. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Suda T, Takahashi T, Golstein P, Nagata S, Cell 1993 75 1169 1178 10.1016/0092-8674(93)90326-L 7505205 (Pubitemid 24006113)
22. Storage, expression and function of Fas ligand, the key death factor of immune cells. Lettau M, Paulsen M, Kabelitz D, Janssen O, Curr Med Chem 2008 15 1684 1696 10.2174/092986708784872384 18673218
23. Cytotoxicity mediated by the Fas ligand (FasL)-activated apoptotic pathway in stem cells. Mazar J, Thomas M, Bezrukov L, Chanturia A, Pekkurnaz G, Yin S, Kuznetsov SA, Robey PG, Zimmerberg J, J Biol Chem 2009 284 22022 22028 10.1074/jbc.M109.032235 19531476
24. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC, Cancer Res 2002 62 4996 5000 12208752 (Pubitemid 34984425)
25. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X, Yang R, Chen W, Wang S, Shi S, Nat Med 2011 17 1594 1601 10.1038/nm.2542 22101767
26. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR, Blood 2003 102 311 319 10.1182/blood-2002-12-3905 12649140 (Pubitemid 36759670)
27. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S, Cell Stem Cell 2012 10 544 555 10.1016/j.stem.2012.03.007 22542159
28. Melphalan: old and new uses of a still master drug for multiple myeloma. Musto P, D'Auria F, Expert Opin Investig Drugs 2007 16 1467 1487 10.1517/13543784.16.9.1467 17714032 (Pubitemid 47491416)
29. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S, Le AD, J Immunol 2009 183 7787 7798 10.4049/jimmunol.0902318 19923445
30. + cells and correlation with disease activity in patients with systemic lupus erythematosus. Sun LY, Zhou KX, Feng XB, Zhang HY, Ding XQ, Jin O, Lu LW, Lau CS, Hou YY, Fan LM, Clin Rheumatol 2007 26 2073 2079 10.1007/s10067-007-0621-2 17447103 (Pubitemid 350120345)
31. Signalling pathways in B cells: implications for autoimmunity. Dörner T, Lipsky PE, Curr Top Microbiol Immunol 2006 305 213 240 10.1007/3-540-29714-6-11 16724808 (Pubitemid 47400260)
32. Abnormal bone turnover in monoclonal gammaopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Vejlgaard T, Abildgaard N, Jans H, Nielsen JL, Heickendorff L, Eur J Haematol 1997 58 104 108 9111591 (Pubitemid 27140395)
33. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. Hjorth-Hansen H, Seifert MF, Börset M, Aarset H, Ostlie A, Sundan A, Waage A, J Bone Miner Res 1999 14 256 263 10.1359/jbmr.1999.14.2.256 9933480 (Pubitemid 29066251)
34. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Blood 2009 114 1803 1812 10.1182/blood-2009-01-201954 19597185
35. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T, Blood 2005 106 3160 3165 10.1182/blood-2004-12-4940 16030194 (Pubitemid 41565914)
36. Pathogenesis and management of bone lesions in multiple myeloma. Bataille R, Manolagas SC, Berenson JR, Hematol Oncol Clin North Am 1997 11 349 361 10.1016/S0889-8588(05)70435-4 9137974 (Pubitemid 27193730)
37. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Gregory CA, Gunn WG, Reyes E, Smolarz AJ, Munoz J, Spees JL, Prockop DJ, Ann N Y Acad Sci 2005 1049 97 106 10.1196/annals.1334.010 15965110 (Pubitemid 40967578)
38. A new insight into the formation of osteolytic lesions in multiple myeloma. Glass DA, Patel MS, Kassenty G, N Engl J Med 2003 349 2479 2480 10.1056/NEJMp038176 14695406 (Pubitemid 38010072)
39. Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis. Fu J, Wang P, Zhang X, Ju S, Li J, Li B, Yu S, Zhang J, Zhang X, Arch Med Sci 2010 6 496 504 22371791
40. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC, Hematol Oncol Clin North Am 2007 21 1007 1034 vii-viii 10.1016/j.hoc.2007.08.007 17996586 (Pubitemid 350051349)
41. Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells. Wang X, Zhang Z, Yao C, Leuk Res 2010 34 1325 1329 10.1016/j.leukres.2010.05.006 20627293
42. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer ZU, Bentrup K, Danka ES, Henkle SL, Scandurro AB, Proc Natl Acad Sci USA 2009 106 3806 3811 10.1073/pnas.0900244106 19234121
43. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Corre J, Labat E, Espagnolle N, Hébraud B, Avet-Loiseau H, Roussel M, Huynh A, Gadelorge M, Cordelier P, Klein B, Moreau P, Facon T, Fournié JJ, Attal M, Bourin P, Cancer Res 2012 72 1395 1406 10.1158/0008-5472.CAN-11-0188 22301101
44. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W, Chayama K, Int J Cancer 2010 127 2323 2333 10.1002/ijc.25440 20473928
45. Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Albarenque SM, Zwacka RM, Mohr A, Stem Cell Res 2011 7 163 171 10.1016/j.scr.2011.05.002 21763624
46. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Ma Y, Hao X, Zhang S, Zhang J, Breast Cancer Res Treat 2012 133 473 485 10.1007/s10549-011-1774-x 21947651
47. Role of bone marrow stromal cells in the growth of human multiple myeloma. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC, Blood 1991 77 2688 2693 1675130
48. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Ciavarella S, Grisendi G, Dominici M, Tucci M, Brunetti O, Dammacco F, Silvestris F, Br J Haematol 2012 157 586 598 10.1111/j.1365-2141. 2012.09082.x 22420897
49. Prospects for translational regenerative medicine. Chen FM, Zhao YM, Jin Y, Shi S, Biotechnol Adv 2012 30 658 672 22138411
50. The dual role of mesenchymal stem cells in tumor progression. Gomes CM, Stem Cell Res Ther 2013 4 42 10.1186/scrt189 23680129
51. The dual effect of mesenchymal stem cells on tumour growth and tumour angiogenesis. Kéramidas M, de Fraipont F, Karageorgis A, Moisan A, Persoons V, Richard MJ, Coll JL, Rome C, Stem Cell Res Ther 2013 4 41 10.1186/scrt195 23628074
52. Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood. Prather WR, Toren A, Meiron M, Expert Opin Biol Ther 2008 8 1241 1250 10.1517/14712598.8.8.1241 18613774
53. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A, Blood 2005 106 1755 1761 10.1182/blood-2005-04-1496 15905186 (Pubitemid 41208591)
54. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Parekkadan B, Tilles AW, Yarmush ML, Stem Cells 2008 26 1913 1919 10.1634/stemcells.2007-0790 18420833
55. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Prockop DJ, Mol Ther 2009 17 939 946 10.1038/mt.2009.62 19337235
56. Mesenchymal stem cells in health and disease. Uccelli A, Moretta L, Pistoia V, Nat Rev Immunol 2008 8 726 736 10.1038/nri2395 19172693
57. Effects of the Fas/Fas-L pathway on fluoride-induced apoptosis in SH-SY5Y cells. Xu B, Xu Z, Xia T, He P, Gao P, He W, Zhang M, Guo L, Niu Q, Wang A, Environ Toxicol 2011 26 86 92 10.1002/tox.20543 19852076
58. Fas/Fas ligand regulation mediates cell death in human Ewing's sarcoma cells treated with melatonin. García-Santos G, Martin V, Rodríguez-Blanco J, Herrera F, Casado-Zapico S, Sánchez- Sánchez AM, Antolín I, Rodríguez C, Br J Cancer 2012 106 1288 1296 10.1038/bjc.2012.66 22382690
59. Immune privilege or inflammation? Insights into the Fas ligand enigma. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F, Nat Med 2012 7 271 274 2001
60. Refractory multiple myeloma treated with homoharringtonine: report of two cases. Yang X, Yang C, Shao K, Ye X, Meng H, Zhou Y, Qian W, Ann Hematol 2007 86 919 921 10.1007/s00277-007-0331-5 17641891
61. Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Lou YJ, Qian WB, Jin J, Leuk Lymphoma 2007 48 1400 1406 10.1080/10428190701411466 17613769 (Pubitemid 47079368)
62. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T, J Exp Med 2006 203 1235 1247 10.1084/jem.20051921 16636132